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Abstract
Introduction: Circumscript, progressing lipoatrophy at the insulin injection sites is an unexplained, however rare
condition in diabetes mellitus.
Case presentation: We report a case of severe localised lipoatrophy developing during insulin pump-treatment
(continuous subcutaneous insulin infusion) with the insulin analogue lispro (Humalog
®) in a woman with type-1
diabetes mellitus. After 11 months of progressing lipoatrophy at two spots on the abdomen, low-dose prednisone
(5-10 mg) p.o. was given at breakfast for 8 months, whereby the atrophic lesions centripetally re-filled with
subcutaneous fat tissue (confirmed by MRI) despite ongoing use of insulin lispro. However, 4 weeks after cessation
of prednisone, lipoatrophy relapsed, but resolved after another 2 months of low-dose prednisone. No further
relapse was noted during 12 months of follow-up on insulin-pump therapy with Humalog
®.
Conclusion: Consistent with an assumed inflammatory nature of the condition, low-dose oral prednisone
appeared to have cured the lipoatrophic reaction in our patient. Our observation suggests a temporary intolerance
of the subcutaneous fat tissue to insulin lispro (Humalog
®), triggered by an unknown endogenous mechanism.
Background
So-called insulin-induced lipoatrophy is a rare, albeit
feared condition mostly in patients with type-1 diabetes
mellitus. It leads to a total loss of subcutaneous fat tissue
at the sites of insulin injections. Neither the pathogenesis
of the condition is known, nor the apparent female pre-
ponderance [1-14]. The clinical appearance is notable for
its lack of inflammatory features. Histopathological
reports were inconsistent: while subcutaneous fat atrophy
and fibrosis was common, immunological abnormalities
were found only in one of the studies (see Table 1). Insu-
lin-induced lipoatrophy has been reported with the use of
various pharmaceutical preparations, long acting or short
acting insulin preparations, insulin analogues or human
insulin, and with subcutaneous injection or continuous
subcutaneous infusion (via insulin pump) treatment alike.
Injection site lipoatrophy was also observed with the use
of the somatostatin-analogue octreotide [8].
Case presentation
We present the case of a 53 year old caucasian woman (R.
P., born 1956), who was diagnosed with type-1 diabetes
mellitus at the age of 13 years. Since 1984 she was treated
by continuous subcutaneous insulin infusion with a porta-
ble insulin pump using human regular insulin, without
any adverse effects. Since 2004, insulin lispro (Humalog
®,
Eli Lilly Deutschland, Bad Homburg, Germany) was used
for insulin pump treatment (currently used device: Accu-
Check Spirit
®, Roche, Burgdorf, Switzerland). There was
no co-morbidity except for Hashimoto’st h y r e o i d i t i s ,
requiring 100 μg levothyroxine once daily for substitution.
There was no evidence for diabetic retinopathy, nephropa-
thy or neuropathy, respectively. HbA1c (normal range 4-
6% of total haemoglobin) was around 8%, body mass index
was 23.8 kg/m
2. In November 2007 and February 2008,
vaccinations against hepatitis A and B were carried out
with a vaccine containing traces of thiomersal (Twinrix
®,
GlaxoSmithKline, Dresden, Germany). Commencing in
May 2008, a lipoatrophic defect developed at the catheter
insertion site on the right side of the abdominal wall, and
after changing to the opposite side, a second lesion devel-
oped there. The size of both lesions increased steadily. In
March 2009 hollows of 6 × 7 cm had developed in the
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try was normal. Immunological serum markers (anti-insu-
lin antibodies, as well as antibodies against mitochondria,
c-ANCA, p-ANCA, and ANA IgG) were negative. Anti-
TPO antibodies, however, were elevated (173 U/ml (nor-
mal < 60 U/ml)). In April 2009, a biopsy was obtained
from the margin of the lipoatrophic area at the right lat-
eral abdominal wall (Figure 1, lower panel). Routine histo-
pathologic examination showed atrophic fat tissue
(lipoatrophy); unfortunately, more detailed histochemical
investigations were not performed. Assuming a potential
adverse effect of Humalog
®, the insulin preparation was
changed-over to rapid-acting genetically engineered
human insulin (Actrapid
®, NovoNordisk, Mainz,
Germany), without obvious benefit. In consideration of an
undefined immunologic pathogenesis, low-dose immuno-
suppressive treatment with 10 mg prednisone once daily
was commenced on June 23, 2009 (with adaptations of the
insulin dosage, as appropriate, to maintain HbA1c
between 7 and 8%). As an immediate effect, no new lipoa-
trophic hollows developed at the catheter insertion sites in
use. In August 2009, the existing hollows started to re-fill,
beginning at the margins (Figure 1, 2). In September 2009,
the daily prednisone dosage was reduced to 5 mg, and
further to 2.5 mg in October 2009. In December 2009, the
patient decided to switch back from human insulin
Table 1 Histopathological findings in insulin-induced circumscript lipoatrophy, as reported in the literature
Previous reports, author Reeves [1] Jermendy [5] Lopez [10] Chantelau [3] present case
cases,n 5 1 4 1
Skin:
immunofluorescence staining* positive negative not analysed negative not analysed
mononuclear cell infiltration mild none not analysed mild not analysed
Subcutaneous tissue:
fat tissue atrophy present absent? present present present
focal fibrosis absent? absent? present present present
lipoblast-like adipocytes absent present absent absent absent
capillary proliferation absent present absent absent absent
immunofluorescence staining* not analysed not analysed negative negative not analysed
lymphocyte infiltration absent not analysed mild mild not analysed
eosinophils infiltration absent not analysed present absent not analysed
mast cells infiltration absent not analysed present absent not analysed
*for IgG, IgA, IgM, C1, C3, and fibrin, or amyloid, respectively
March 2009        April 2009             July 2009           October 2009 
Figure 1 Follow-up of lipoatrophic sites, before, during, and after prednisone therapy. Series of photographs showing lipoatrophic areas
on both sides of the umbilicus (upper panel: left side, lower panel: right side). Photographs as of March 2009 and April 2009 were taken before
prednisone therapy. In April 2009, a biopsy was taken from the right side, which healed uneventfully, see lower panel. Low-dose oral prednisone
was administered from the last week of June 2009 until March 2010, and from May 2010 until June 2010. To be continued on Figure 2.
Chantelau et al. Diabetology & Metabolic Syndrome 2011, 3:33
http://www.dmsjournal.com/content/3/1/33
Page 2 of 5(Actrapid
®) to insulin lispro (Humalog
®), while the lipoa-
trophic hollows continued to re-fill with subcutaneous fat
tissue rather than fibrous scar tissue (confirmed by MRI,
see Figure 3). In March 2010, when the lipoatrophy was
almost cured, prednisone was discontinued. The patient
was advised to use the previously lipoatrophic areas again
for catheter insertion. However, about 4 weeks later, pre-
dnisone had to be resumed because lipoatrophy had
relapsed. By June 2010, after another 2 months of predni-
sone therapy, the lipoatrophic areas were cured again (Fig-
ure 2) and prednisone was tapered off. During the
following 12 months on unchanged insulin-pump therapy
using insulin lispro, no relapse of the lipoatrophy was
noted (Figure 2).
However, 3 months after cessation of prednisone treat-
ment, in both hands cheiroarthropathy developed with
thickened flexor digitorum tendons and edema of the ten-
don sheaths, as evidenced by MRI [15]. Rheumatoid
arthritis was ruled out on laboratory and imaging studies.
The condition was markedly alleviated by physiotherapy.
Discussion
Our present observation in an adult patient is the first to
show an acutely relapsing circumscript lipoatrophy at the
sites of subcutaneous infusion of insulin lispro, which fully
resolved by low-dose oral corticosteroid treatment. In a
previous patient of ours, whose lipoatrophies seemingly
stopped after changing from injections to insulin pump
treatment [3], a relapse occurred after 5 years of insulin
pump treatment and resolved during oral corticosteroid
treatment (given to treat newly diagnosed arteriitis tem-
poralis [E.A. Chantelau, unpublished observation]).
In contrast to adult patients, in whom insulin lipoatro-
phy rarely resolves spontaneously [2,7,10,11,14], insulin
lipoatrophy sometimes resolved spontaneously in children
[5,6,12,16]. Hence, treatment of the condition is particu-
larly warranted for adults. Changing the insulin brand, or
changing from injections to continuous subcutaneous
insulin infusion [3,11] seemed to be equally ineffective.
Empirical treatment based on topical corticosteroid injec-
tions (injection of dexamethasone into the lipoatrophic
lesions) had resulted in return of subcutaneous fat tissue
in an adult [17,18] and in a child [9], but not in an infant
[12]. Recently, topical disodium cromoglycate ointment
was found effective in lipoatrophy of short duration by
Lopez et al., who also reported that a long-standing
chronic lipoatrophy was unresponsive to either topical dis-
odium cromoglycate ointment or corticosteroid injections
[10].
The present case report adds to the evidence, that a
subclinical, subacute inflammatory reaction may be
involved in the pathogenesis of insulin-induced lipoatro-
phy, since the destructive process may be suppressed and
even reversed by administration of anti-inflammatory
compounds (e.g. corticosteroids, disodium cromoglycate
ointment). This process is different from the local inflam-
matory reaction that regularly occurs in the subcuta-
neous fat tissue after injection of insulin, insulin
November 2009      April 2010            June 2010            July 2011 
Figure 2 Follow-up of lipoatrophic sites, before, during, and after prednisone therapy pt. 2. Continuation from Figure 1. Low-dose oral
prednisone was administered from the last week of June 2009 until March 2010, and from May 2010 until June 2010. The photographs as of
July 2011 were taken 12 months after cessation of prednisone therapy.
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underlying mechanisms of injection-induced subcuta-
neous lipoatrophy remain to be determined. A personal
susceptibility might be involved, as has been suggested by
Atmaca et al. [8], which might be transitory, as our case
seems to indicate. The trigger of such a transitory intoler-
ance remains unknown, as well as the female preponder-
ance of the condition.
Conclusion
In conclusion, the case of our patient supports the use
of prolonged low-dose corticosteroid treatment to cure
progressive insulin-induced lipoatrophy. A careful adap-
tation of the insulin dose is mandatory in order to avoid
corticosteroid-induced hyperglycaemia.
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